#Israel #Caesarea #IceCure Medical #Cryoablation #ProSense Cryoablation

IceCure Medical's ProSense® Cryoablation at the St. Gallen Conference

IceCure Medical Ltd. recently made headlines at the St. Gallen International Breast Cancer Conference held in Vienna, Austria, where six studies on its ProSense® Cryoablation technology were featured. This technology is known for its minimally invasive approach to destroying cancerous tumors by applying freezing techniques, serving as a commendable alternative to traditional surgical methods.

Highlights from the Conference

The conference, which took place from March 12 to 15, 2025, attracted notable oncologists and breast surgeons, emphasizing the growing importance of innovative treatment options for breast cancer. Among the key contributions was an abstract titled "The Impact of Adjuvant Treatment After Cryoablation in Early-Stage, Low-Risk Breast Cancer ICE3 Trial 5-Year Ipsilateral Breast Tumor Recurrence (IBTR)," led by Dr. Richard Fine from the United States.

Dr. Fine's study reported promising results indicating that patients with early-stage, low-risk breast cancer who underwent cryoablation with ProSense® showed overall recurrence rates akin to those who had traditional lumpectomy surgeries. The results demonstrated that end-of-treatment success rates remained robust, reinforcing the viability of the ProSense® method as a strategic treatment option.

In addition, Dr. Ava Kwong from Hong Kong presented findings that expanded the inclusion criteria of the ICE3 study to encompass triple-negative breast cancer, accelerating the potential benefits of cryoablation for a wider patient demographic. This research demonstrated that ProSense® effectively treats various subtypes of breast cancer, thus underscoring its flexibility and applicability across different patient ages and cancer stages.

Further studies presented included evaluations by leading researchers on cryoablation's effectiveness compared to other emerging techniques like radiofrequency and microwave ablation. The seminars also shed light on percutaneous ultrasound-guided cryoablation, showcasing its feasibility in non-surgical patients—a critical consideration for those preferring alternatives to invasive surgery.

The Significance of ProSense® Cryoablation

IceCure's technology stands out due to its use of liquid nitrogen to create expansive lethal zones for tumor destruction. This method not only enhances patient recovery times and minimizes discomfort compared to conventional surgery but also represents a significant step forward in offering outpatient procedures that can be accomplished in a comfortable office setting.

The ability of the ProSense® to effectively treat tumors in critical areas such as the breast, lung, kidney, and liver makes it a versatile tool in modern oncology, promising favorable outcomes without the intricacies and risks associated with surgical interventions.

Eyal Shamir, CEO of IceCure, expressed appreciation for the ongoing support from the medical community and researchers, emphasizing a collective goal of advancing women's health through innovation and collaborative efforts.

The findings from these recent studies will soon be published in the scientific journal, The Breast, further validating the significant role of ProSense® in the medical field.

Future Directions

IceCure Medical's accomplishments at the St. Gallen Conference mark an important milestone in the evolution of cryoablation technology as a robust alternative to surgical intervention. As studies continue to emerge, the hope is that more patients will be given the opportunity to benefit from these innovative, less invasive treatment options. The focus now shifts to the comprehensive analysis of these findings and an accelerated pathway for the regulatory approvals necessary to broaden access to ProSense® Cryoablation, reinforcing IceCure's mission of improving outcomes in breast cancer treatment.

In conclusion, the developments shared at the St. Gallen Conference not only highlight the clinical efficacy of ProSense® but also expand the horizons of breast cancer treatment methodologies as healthcare providers seek ways to enhance the quality of care delivered to patients.